Drugs prepared from botulinum toxin are injected in microscopic amounts in distinct muscles that involve treatment. The drug binds towards the nerve terminals and blocks the release of acetylcholine, soothing the focused muscles. On August two, 2010, the US FDA introduced the acceptance of incobotulinumtoxinA (Xeomin®) for the treatment https://botulinumtoxins03583.salesmanwiki.com/9677357/the_ultimate_guide_to_botulinum_toxins_in_humans